Potential conflict of interest: Nothing to report.
Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations
Version of Record online: 18 DEC 2013
Copyright © 2013 The Authors. HEPATOLOGY published by Wiley on behalf of the American Association for the Study of Liver Diseases.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 59, Issue 2, pages 661–670, February 2014
How to Cite
Kleiner, D. E., Chalasani, N. P., Lee, W. M., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Hayashi, P. H., Davern, T. J., Navarro, V., Reddy, R., Talwalkar, J. A., Stolz, A., Gu, J., Barnhart, H., Hoofnagle, J. H. and for the Drug-Induced Liver Injury Network (DILIN) (2014), Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology, 59: 661–670. doi: 10.1002/hep.26709
The DILIN network is structured as an U01 cooperative agreement supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health (NIH) with funds provided by the following grants: U01DK065193 (University of Connecticut); U01DK065211 (University of Indiana [Purdue]); U01DK065238 (University of California San Francisco/CPMC); U01DK065184 (University of Michigan [Ann Arbor]); U01DK065201 (University of North Carolina Chapel Hill, Asheville, Carolinas Medical Center, Duke); U01DK83023 (University of Texas-Southwestern); U01DK083020 (University of Southern California, UCLA Pfleger Liver Institute); U01DK08992 (Mayo Clinic); U01DK083027 (Thomas Jefferson and University of Pennsylvania); and U01DK065176 (Duke Clinical Research Institute as Data Coordinating Center). This work was supported, in part, by the Intramural Program of the National Cancer Institute, National Institutes of Health. This study is DILIN publication no. 23.
- Issue online: 29 JAN 2014
- Version of Record online: 18 DEC 2013
- Accepted manuscript online: 28 AUG 2013 10:46AM EST
- Manuscript Accepted: 22 AUG 2013
- Manuscript Revised: 16 JUL 2013
- Manuscript Received: 8 MAR 2013
- 9US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51:2117-2126., , , , , , et al.;
- 10Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH Drug-Induced Liver Injury Network (DILIN) Study. Gastroenterology 2007;132:A773., , , , , , et al.
- 11Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 1999..
- 12Hepatic injury due to drugs and toxins. In: MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, eds. Pathology of the Liver. London: Churchill Livingstone; 2002:621-710., :
- 13Pathology of the Liver. London: Churchill Livingstone; 2002., , , , , .